MA34296B1 - Composition retard injectable antipsychotique - Google Patents
Composition retard injectable antipsychotiqueInfo
- Publication number
- MA34296B1 MA34296B1 MA35428A MA35428A MA34296B1 MA 34296 B1 MA34296 B1 MA 34296B1 MA 35428 A MA35428 A MA 35428A MA 35428 A MA35428 A MA 35428A MA 34296 B1 MA34296 B1 MA 34296B1
- Authority
- MA
- Morocco
- Prior art keywords
- composition
- biodegradable
- injectable
- retardant
- rates
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000000561 anti-psychotic effect Effects 0.000 title abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000007943 implant Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 abstract 1
- 229960001534 risperidone Drugs 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION QUI PEUT ÊTRE UTILISÉE POUR ADMINISTRER UN MÉDICAMENT ANTIPSYCHOTIQUE TEL QUE LA RISPÉRIDONE SOUS FORME D'UN IMPLANT BIODÉGRADABLE DE FORMATION IN-SITU POUR LA LIBÉRATION PROLONGÉE ASSURANT DES TAUX PLASMATIQUES THÉRAPEUTIQUES DÈS LE PREMIER JOUR. LA COMPOSITION SE PRÉSENTE SOUS LA FORME D'UNE SUSPENSION MÉDICAMENTEUSE SUR UN COPOLYMÈRE OU UNE SOLUTION DE COPOLYMÈRES BIODÉGRADABLE ET BIOCOMPATIBLE UTILISANT DES SOLVANTS MISCIBLES QUI EST ADMINISTRÉE SOUS FORME LIQUIDE. UNE FOIS LA COMPOSITION EN CONTACT AVEC LES LIQUIDES CORPORELS, LA MATRICE POLYMÈRE DURCIT, RETENANT LE MÉDICAMENT, FORMANT UN IMPLANT SOLIDE OU SEMI-SOLIDE QUI LIBÈRE LE MÉDICAMENT EN CONTINU. DES TAUX PLASMATIQUES THÉRAPEUTIQUES DU MÉDICAMENT PEUVENT ÊTRE OBTENUS DÈS LE PREMIER JOUR JUSQU'AU MOINS 14 JOURS OU PLUS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382154.2A EP2394664B1 (fr) | 2010-05-31 | 2010-05-31 | Compositions pour implants biodégradables in situ injectables |
| PCT/EP2011/059000 WO2011151355A1 (fr) | 2010-05-31 | 2011-05-31 | Composition retard injectable antipsychotique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34296B1 true MA34296B1 (fr) | 2013-06-01 |
Family
ID=43301889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35428A MA34296B1 (fr) | 2010-05-31 | 2011-05-31 | Composition retard injectable antipsychotique |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US10085936B2 (fr) |
| EP (2) | EP2394664B1 (fr) |
| JP (1) | JP5882993B2 (fr) |
| KR (1) | KR101784330B1 (fr) |
| CN (1) | CN103002917B (fr) |
| AP (1) | AP3524A (fr) |
| AU (1) | AU2011260318B2 (fr) |
| BR (1) | BR112012030686B1 (fr) |
| CA (1) | CA2800111C (fr) |
| CL (1) | CL2012003350A1 (fr) |
| CY (2) | CY1117964T1 (fr) |
| DK (2) | DK2394664T3 (fr) |
| EA (1) | EA024155B1 (fr) |
| ES (2) | ES2589106T3 (fr) |
| HR (2) | HRP20161049T1 (fr) |
| HU (2) | HUE029895T2 (fr) |
| IL (1) | IL223129A (fr) |
| LT (2) | LT2394664T (fr) |
| MA (1) | MA34296B1 (fr) |
| ME (1) | ME02501B (fr) |
| MX (1) | MX338373B (fr) |
| MY (1) | MY161930A (fr) |
| NZ (1) | NZ604342A (fr) |
| PH (1) | PH12012502338B1 (fr) |
| PL (2) | PL2394664T3 (fr) |
| PT (2) | PT2394664T (fr) |
| RS (1) | RS55190B1 (fr) |
| SG (1) | SG185775A1 (fr) |
| SI (2) | SI2394664T1 (fr) |
| SM (2) | SMT201600320B (fr) |
| UA (1) | UA108885C2 (fr) |
| WO (1) | WO2011151355A1 (fr) |
| ZA (1) | ZA201209346B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) * | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| EP2529757B1 (fr) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Formulation d'implant de Paliperidone |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| SI2394663T1 (sl) | 2010-05-31 | 2022-02-28 | Laboratorios Farmaceuticos Rovi, S.A. | Sestave za injicirane biološko razgradljive vsadke in situ |
| LT2529756T (lt) * | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| EP2986278A1 (fr) | 2013-03-11 | 2016-02-24 | DURECT Corporation | Composition injectable à libération contrôlée comprenant un véhicule liquide à haute viscosité |
| WO2016199170A2 (fr) * | 2015-06-10 | 2016-12-15 | Cipla Limited | Particules de palmitate de palipéridone et compositions à base de celles-ci |
| CA3057438A1 (fr) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Formulations d'olanzapine a liberation prolongee |
| CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
| PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| CN110420212A (zh) * | 2019-08-19 | 2019-11-08 | 韩自勤 | 一种用于治疗精神分裂症组合物及其制备方法 |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| US12594236B2 (en) | 2021-07-16 | 2026-04-07 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
| EP4527389A4 (fr) * | 2022-05-18 | 2026-05-06 | Farm Rovi Lab Sa | Compositions injectables à libération prolongée destinées à être utilisées dans le cadre du traitement par rispéridone en association avec des inhibiteurs de l'enzyme cyp2d6 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| BE758156R (fr) | 1970-05-13 | 1971-04-28 | Ethicon Inc | Element de suture absorbable et sa |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4523591A (en) | 1982-10-22 | 1985-06-18 | Kaplan Donald S | Polymers for injection molding of absorbable surgical devices |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5620700A (en) | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
| US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| ATE288270T1 (de) | 1993-11-19 | 2005-02-15 | Janssen Pharmaceutica Nv | Mikroverkapselte 1,2-benzazole |
| JP2002512597A (ja) | 1996-12-20 | 2002-04-23 | アルザ コーポレイション | 注射可能な貯留槽ゲル組成物およびこの組成物の製造方法 |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6331317B1 (en) * | 1999-11-12 | 2001-12-18 | Alkermes Controlled Therapeutics Ii Inc. | Apparatus and method for preparing microparticles |
| AU2001237221A1 (en) * | 2000-01-11 | 2001-07-24 | Roland Bodmeier | Implants, particles |
| US6604561B2 (en) * | 2000-02-11 | 2003-08-12 | Medical Instill Technologies, Inc. | Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial |
| WO2004011054A2 (fr) * | 2002-07-31 | 2004-02-05 | Alza Corporation | Compositions de depot polymere multimode injectables et leurs utilisations |
| WO2004064752A2 (fr) * | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Procede de preparation de microparticules a liberation prolongee |
| US20050003007A1 (en) | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
| JP2008518881A (ja) * | 2003-07-18 | 2008-06-05 | オークウッド ラボラトリーズ，エル．エル．シー． | 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止 |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| DE102005031868A1 (de) * | 2005-07-04 | 2007-01-18 | Biotronik Vi Patent Ag | Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| FR2908775B1 (fr) * | 2006-11-17 | 2012-08-31 | Biomatlante | Hydrogel et ses applications biomedicales |
| DK3660073T3 (da) | 2007-02-15 | 2023-09-18 | Tolmar International Ltd | Poly(lactid-co-glycolid) med lav sprængning |
| WO2008143992A2 (fr) * | 2007-05-18 | 2008-11-27 | Durect Corporation | Formulations à dépôt amélioré |
| BRPI0811319A2 (pt) * | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
| CL2008003305A1 (es) * | 2007-11-06 | 2009-06-05 | M/S Panacea Biotec Ltd | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. |
| PL2323623T3 (pl) * | 2008-08-12 | 2017-04-28 | Novartis Ag | Kompozycje farmaceutyczne |
| EP2529757B1 (fr) | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Formulation d'implant de Paliperidone |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| SI2394663T1 (sl) | 2010-05-31 | 2022-02-28 | Laboratorios Farmaceuticos Rovi, S.A. | Sestave za injicirane biološko razgradljive vsadke in situ |
| LT2529756T (lt) | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
-
2010
- 2010-05-31 ES ES10382154.2T patent/ES2589106T3/es active Active
- 2010-05-31 PL PL10382154.2T patent/PL2394664T3/pl unknown
- 2010-05-31 SI SI201031270A patent/SI2394664T1/sl unknown
- 2010-05-31 DK DK10382154.2T patent/DK2394664T3/en active
- 2010-05-31 HU HUE10382154A patent/HUE029895T2/en unknown
- 2010-05-31 PT PT103821542T patent/PT2394664T/pt unknown
- 2010-05-31 LT LTEP10382154.2T patent/LT2394664T/lt unknown
- 2010-05-31 EP EP10382154.2A patent/EP2394664B1/fr active Active
-
2011
- 2011-05-31 UA UAA201214486A patent/UA108885C2/ru unknown
- 2011-05-31 ME MEP-2016-178A patent/ME02501B/fr unknown
- 2011-05-31 MX MX2012013937A patent/MX338373B/es active IP Right Grant
- 2011-05-31 DK DK11725383.1T patent/DK2575890T3/en active
- 2011-05-31 JP JP2013512879A patent/JP5882993B2/ja active Active
- 2011-05-31 EA EA201201569A patent/EA024155B1/ru unknown
- 2011-05-31 SG SG2012087136A patent/SG185775A1/en unknown
- 2011-05-31 AU AU2011260318A patent/AU2011260318B2/en active Active
- 2011-05-31 RS RS20160730A patent/RS55190B1/sr unknown
- 2011-05-31 PT PT117253831T patent/PT2575890T/pt unknown
- 2011-05-31 PH PH1/2012/502338A patent/PH12012502338B1/en unknown
- 2011-05-31 HU HUE11725383A patent/HUE029056T2/en unknown
- 2011-05-31 LT LTEP11725383.1T patent/LT2575890T/lt unknown
- 2011-05-31 AP AP2012006626A patent/AP3524A/xx active
- 2011-05-31 EP EP11725383.1A patent/EP2575890B1/fr active Active
- 2011-05-31 KR KR1020127033021A patent/KR101784330B1/ko active Active
- 2011-05-31 MY MYPI2012701044A patent/MY161930A/en unknown
- 2011-05-31 MA MA35428A patent/MA34296B1/fr unknown
- 2011-05-31 CN CN201180026475.2A patent/CN103002917B/zh active Active
- 2011-05-31 NZ NZ604342A patent/NZ604342A/en unknown
- 2011-05-31 WO PCT/EP2011/059000 patent/WO2011151355A1/fr not_active Ceased
- 2011-05-31 BR BR112012030686-3A patent/BR112012030686B1/pt active IP Right Grant
- 2011-05-31 SI SI201130939A patent/SI2575890T1/sl unknown
- 2011-05-31 HR HRP20161049TT patent/HRP20161049T1/hr unknown
- 2011-05-31 ES ES11725383.1T patent/ES2592527T3/es active Active
- 2011-05-31 CA CA2800111A patent/CA2800111C/fr active Active
- 2011-05-31 PL PL11725383.1T patent/PL2575890T3/pl unknown
-
2012
- 2012-11-19 IL IL223129A patent/IL223129A/en active IP Right Grant
- 2012-11-29 CL CL2012003350A patent/CL2012003350A1/es unknown
- 2012-11-30 US US13/690,647 patent/US10085936B2/en active Active
- 2012-12-10 ZA ZA2012/09346A patent/ZA201209346B/en unknown
-
2016
- 2016-08-29 HR HRP20161100TT patent/HRP20161100T1/hr unknown
- 2016-08-31 CY CY20161100858T patent/CY1117964T1/el unknown
- 2016-08-31 CY CY20161100857T patent/CY1117969T1/el unknown
- 2016-09-15 SM SM201600320T patent/SMT201600320B/it unknown
- 2016-09-15 SM SM201600321T patent/SMT201600321B/it unknown
-
2018
- 2018-04-04 US US15/944,894 patent/US10182982B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
| MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
| KR20180080189A (ko) | 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물 | |
| EP1786400A4 (fr) | Compositions pharmaceutiques permettant la liberation progressive de composes bioactifs | |
| MY167123A (en) | Conveniently implantable sustained release drug compositions | |
| BR0213143A (pt) | Composições lìquidas para administração oral contendo guaifenesina e um copolìmero de bloco polioxialquileno | |
| EA201100313A1 (ru) | Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом | |
| EP2101757A4 (fr) | Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé | |
| EA201201569A1 (ru) | Инъекционная композиция пролонгированного действия для введения антипсихотического препарата | |
| BR0308137A (pt) | Formulações de droga de liberação constante contendo um peptìdeo veìculo | |
| JP2008513506A5 (fr) | ||
| WO2008103409A3 (fr) | Compositions de chloroquine couplée à des anticorps et autres protéines et procédés pour leur synthèse | |
| MA44206A (fr) | Comprimé orodispersible comprenant estetrol | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| NZ595127A (en) | Stable pharmaceutical composition for atherosclerosis | |
| MY147310A (en) | A solid pharmaceutical composition containing 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid or a salt thereof, a fat and oil-like substace having low melting point and a low viscosity binder | |
| JP2015531373A5 (fr) | ||
| MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| TW200815410A (en) | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | |
| RS60510B1 (sr) | Dozni režim za propuštene doze injektibilnih estara paliperidona sa produženim delovanjem | |
| MX388825B (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| MA33602B1 (fr) | Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide | |
| MA32635B1 (fr) | Produit medicamenteux et traitement associe | |
| TW200501946A (en) | Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight | |
| RU2552290C1 (ru) | Соединения опиоидных антагонистов и их применение при лечении склеродермии |